Astellas Responds To "Approvable" Letter For Prograf MR Kidney Transplant Claim
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma has responded to an FDA "approvable" letter for use of the once-daily immunosuppressant Prograf MR (tacrolimus modified-release) to prevent rejection of kidney transplants, the Japanese firm announced Sept. 19
You may also be interested in...
Astellas Sees Further FDA Action On Prograf MR In Early 2008
Firm and partner FibroGen also plan response to FDA’s clinical hold on their novel EPO candidates by year end.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).